ArticleEJNMMI radiopharmacy and chemistry2026
The use of mass cytometry (CyTOF) to evaluate the cellular uptake of stable radiopharmaceutical surrogates in single cells: a proof-of-concept study.
Article in EJNMMI radiopharmacy and chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCurrent methods for assessing radiopharmaceutical uptake are based on scintillation counting (e.g., γ-counting) or imaging techniques, such as positron emission tomography (PET) and single photon emission computed tomography (SPECT), which evaluate the average radiopharmaceutical uptake in biological samples. Single-cell analysis of radiopharmaceutical uptake and biodistribution would provide a better understanding of the possible heterogeneous uptake in cellular populations and organs, with the potential to improve current dosimetry and toxicity assessments. In this proof-of-concept study, we evaluate the use of mass cytometry (CyTOF) as an analytical tool to study the uptake of non-radioactive radiopharmaceutical surrogates at the single-cell level.
resultsThe preclinical immunoconjugate DOTA-cAC10, targeting CD30 (a receptor overexpressed in lymphomas), was labeled either with radioactive lutetium-177 (
conclusionsThe sensitivity of CyTOF enabled discrimination of uptake between cell models even at low metal-to-antibody stoichiometric ratios. It also revealed intercellular variability in uptake that can only be captured with single-cell methods. Overall, we showed that CyTOF is a robust, high-throughput, multiplexed approach for characterizing the cellular uptake of stable radiopharmaceutical surrogates at single-cell resolution, paving the way for future studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.